Compare EBAY & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EBAY | TAK |
|---|---|---|
| Founded | 1995 | 1781 |
| Country | United States | Japan |
| Employees | N/A | 47455 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.1B | 52.4B |
| IPO Year | 1998 | N/A |
| Metric | EBAY | TAK |
|---|---|---|
| Price | $108.45 | $15.95 |
| Analyst Decision | Buy | |
| Analyst Count | 27 | 0 |
| Target Price | ★ $99.44 | N/A |
| AVG Volume (30 Days) | ★ 4.1M | 3.0M |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | 1.20% | ★ 3.24% |
| EPS Growth | ★ 10.15 | N/A |
| EPS | ★ 1.12 | N/A |
| Revenue | ★ $17,902,000,000.00 | N/A |
| Revenue This Year | $10.48 | $0.16 |
| Revenue Next Year | $5.08 | $1.22 |
| P/E Ratio | $97.90 | ★ $41.25 |
| Revenue Growth | ★ 11.56 | N/A |
| 52 Week Low | $72.84 | $12.99 |
| 52 Week High | $119.31 | $18.90 |
| Indicator | EBAY | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 49.12 | 46.93 |
| Support Level | $87.12 | $15.63 |
| Resistance Level | $111.38 | $16.48 |
| Average True Range (ATR) | 3.15 | 0.21 |
| MACD | -0.80 | 0.07 |
| Stochastic Oscillator | 25.83 | 77.27 |
Founded in 1995, eBay operates one of the world's largest online marketplaces, connecting buyers and sellers across more than 190 markets. In 2025, the firm generated $11.1 billion in revenue on nearly $80 billion of gross merchandise volume, serving 135 million active buyers and 18 million active sellers (users who closed at least one transaction in the past year). The firm monetizes its marketplace primarily through transaction fees and advertising, with 52% of revenue derived from the US and the remainder from international markets. In a bid to expand its reach among Generation Z and in the recommerce sector, eBay announced the $1.2 billion acquisition of fashion resale app Depop from Etsy in early 2026.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.